In a news release early Tuesday, the pharmaceutical company and the Medicines Patent Pool, a U.N.-backed public health organization, announced that a voluntary licensing agreement had been signed for Pfizer’s investigational treatment for COVID-19.
“Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people,” Pfizer Chairman and CEO Albert Bourla said in a statement.
The companies said early results from their Phase 3 clinical trial showed that molnupiravir reduced the risk of hospitalization or death from the illness by about half in the study’s participants, who had underlying health conditions that put them at a higher risk of developing severe COVID-19.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.